133053-19-7 Usage
Description
Go-6983 (133053-19-7) potent and pan-specific, ATP-competitive protein kinase C inhibitor. PKC isotype IC50s= 7, 7, 6, 10 and 60 nM for PKC α, β, γ, δ, ζ respectively.1 Suppresses stress induced HSP27 disassociation.2 Maintains rat embryonic stem cell pluripotency.3 Attenuates myocardial ischemia/reperfusion injury.4
Uses
Different sources of media describe the Uses of 133053-19-7 differently. You can refer to the following data:
1. Go 6983, is a protein kinase C (PKC) inhibitor.Potent PKC Inhibitor
2. GO6983 has been used as a protein kinase C (PKC) inhibitor to study its effects on the nuclear import. It has also been used as a supplement in Fc medium to culture mouse embryonic stem (mES) cells on mitomycin C treated mouse embryonic fibroblasts (MEFs).
Biological Activity
Broad spectrum protein kinase C (PKC) inhibitor (IC 50 values are 7, 7, 6, 10, 60 and 20000 nM for PKC α , PKC β , PKC γ , PKC δ , PKC ζ and PKC μ respectively). Displays cardioprotective properties; reduces polymorphonuclear leukocyte adherence and infiltration following myocardial ischemia/reperfusion injury.
Biochem/physiol Actions
Protein kinase C (PKC) inhibitor that selectively inhibits several PKC isozymes (IC50 = 7 nM for PKCα and PKCβ; 6 nM for PKCγ; 10 nM for PKCδ; and 60 nM for PKCζ), but does not inhibit PKCμ (IC50 = 20 mM).
References
1) Gschwendt et al. (1996), Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase C isoenzymes; FEBS Lett., 392 77
2) Kato et al. (2001), Protein kinase inhibitors can suppress stress-induced dissociation of Hsp27; Cell Stress Chaperones, 6 16
3) Rajendran et al. (2013), Inhibition of protein kinase C signaling maintains rat embryonic stem cell pluripotency; J. Biol. Chem., 288 24351
4) Young et al. (2005), Go 6983: a fast acting protein kinase C inhibitor that attenuates myocardial ischemia/reperfusion injury; Cardiovasc, Drug Rev., 23 255
Check Digit Verification of cas no
The CAS Registry Mumber 133053-19-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,0,5 and 3 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 133053-19:
(8*1)+(7*3)+(6*3)+(5*0)+(4*5)+(3*3)+(2*1)+(1*9)=87
87 % 10 = 7
So 133053-19-7 is a valid CAS Registry Number.
InChI:InChI=1/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5,7-10,13-15,27H,6,11-12H2,1-3H3,(H,28,31,32)
133053-19-7Relevant articles and documents
NK CELL ACTIVATING MOLECULES, NK CELLS AND PHARMACEUTICAL COMPOSITONS COMPRISING THE SAME
-
Page/Page column 32, (2008/12/04)
The present invention relates to a compound represented by specific Formula 1; a process for preparing the same; NK cells treated with said compound; a process for treating NK cells with said compound; and a pharmaceutical composition comprising said compound or said NK cells. The present compound of Formula 1 may outstandingly increase expression of natural cytotoxicity receptors on NK cells such as NCR1, NCR2 and NCR3 and death ligands such as FasL and TRAIL. Thus, NK cel ls treated with the present compound have highly increased cytotoxicity against target cells such as cancer cells and host cells infected with viruses. Therefore, the present compound or NK cells treated with the same may be usefully used as a medical use such as anticancer agents and antiviral agents.
